-
公开(公告)号：US20230089969A1
公开(公告)日：2023-03-23
申请号：US17817033
申请日：2022-08-03
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
Patent Agency Ranking
公开(公告)号：US20230087745A1
公开(公告)日：2023-03-23
申请号：US17821837
申请日：2022-08-24
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ , Edward VAN DEN BRINK , Dennis VERZIJL
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20220033510A1
公开(公告)日：2022-02-03
申请号：US17360438
申请日：2021-06-28
Applicant: GENMAB A/S , BioNTech SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , A61K39/395 , G01N33/569
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
公开(公告)号：US20210369842A1
公开(公告)日：2021-12-02
申请号：US17289602
申请日：2019-11-06
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK
Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.
-
公开(公告)号：US20200062853A1
公开(公告)日：2020-02-27
申请号：US16316534
申请日：2017-07-14
Applicant: GENMAB A/S , BIONTECH AG
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Friederike GIESEKE , Ugur SAHIN
IPC: C07K16/28 , G01N33/569 , A61K39/395
Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
-
16.发明公开公开(公告)号：US20230399403A1
公开(公告)日：2023-12-14
申请号：US18035172
申请日：2021-11-11
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Karsten BECKMANN , Claudia PAULMANN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Alexander MUIK , Ivan KUZMANOV
IPC: C07K16/28 , G01N33/574
CPC classification number: C07K16/2818 , G01N33/57492 , C07K2317/565 , G01N2333/70521 , C07K2317/92 , C07K2317/76 , C07K2317/24
Abstract: The present disclosure relates to antibodies having the ability of binding to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody having the ability of binding to the immune checkpoint protein PD-1, such as human PD-1, or a nucleic acid encoding such an antibody, or a composition comprising said antibody or nucleic acid.
-
-
-
-
-
Search Results
16
records
(took 0.016 seconds)
